OxThera AB’s product Oxabact has been granted an Orphan Drug Designation in the European Union for treatment of Short Bowel Syndrome (SBS).
Oxabact is an oral product composed of highly concentrated live bacteria (Oxalobacter formigenes). OxThera is currently pursuing a clinical development program in the EU and in the US for the treatment of patients suffering from Primary
Hyperoxaluria.
“We are happy to announce that Oxabact(R) is now also recognized as a potential treatment for Short Bowel Syndrome. OxThera believe that Oxabact(R) would be an excellent add-on therapy in SBS patients and would help the underlying gastritis and malabsorption in the gut, as well as subsequently reducing plasma oxalate and preventing kidney disease,” said Elisabeth Lindner, CEO of OxThera.
Oxabact previously holds orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria.
